Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

Initial Statement of Beneficial Ownership

Derivative Acquisition Under Employee Benefit Plan

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Carolyn R. Bertozzi	Independent Director Show All	Initial Statement of Beneficial Ownership (Initial Statement of Beneficial Ownership)	—	—	—	2.0K	—	—	08 Dec 2025	08 Dec 2025 - 08 Dec 2025
	—	Open Market Disposition (Open Market Disposition)	-162.7K	-0.01817%	-0.2%	92.2M	1,073.7 - 1,110.5	-178.4M	26 Nov 2025	25 Nov 2025 - 25 Nov 2025
	—	Open Market Disposition (Open Market Disposition)	-142.3K	-0.015893%	-0.2%	92.4M	1,068.2 - 1,073.6	-152.1M	25 Nov 2025	24 Nov 2025 - 24 Nov 2025
	—	Open Market Disposition (Open Market Disposition)	-105.3K	-0.011763%	-0.1%	92.5M	1,050.3 - 1,066.2	-111.5M	24 Nov 2025	21 Nov 2025 - 21 Nov 2025
	—	Sale	-305.0K	—	—	—	1,059.7 - 1,059.7	-323.2M	24 Nov 2025	24 Nov 2025 - 24 Nov 2025
	—
	—
	—
	—
Kimberly H. Johnson
Gabrielle E. Greene-Sulzberger
Jon R. Moeller
Juan Ricardo Luciano
William G. Kaelin
Jamere Jackson
Mary Lynne Hedley
Jon Erik Fyrwald
Katherine Baicker
Ralph Alvarez
	—
	—
Adrienne Brown
Adrienne Brown
	—
Donald A. Zakrowski
	—
	—
	—
	—
David A. Ricks